However, according to a separate interim analysis of the DESTINY-Lung01, fam-trastuzumab deruxtecan has demonstrated a 24.5% (95% CI, 13.3–38.9%) ORR in HER2-overexpressed, immunohistochemistry (IHC) 2+ or 3+, HER2 mutation-negative NSCLC, which may be related to HER2 amplification. Here, ERBB2 is linked to non-small cell lung carcinoma.